Showing results (241-250 of 253) with videos related to

Sort By:
Pageof 26
Breast Cancer Research and Treatment|August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility studyElaine M Walsh, Ayca Gucalp, Sujata Patil, et al.
CA: a Cancer Journal for Clinicians|February 24, 2023
Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancerMiriam B Garcia, Keri L Schadler, Joya Chandra, et al.
Veterinary Microbiology|May 17, 2011
Zoonotic cases of camelpox infection in IndiaB C Bera, K Shanmugasundaram, Sanjay Barua, et al.
Cancer Research|September 27, 2017
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4<sup>+</sup> TILs in the Presence of PD-L1<sup>+</sup> TAMsAustin K Mattox, Jina Lee, William H Westra, et al.
JCI Insight|July 27, 2018
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivationElizabeth A Wellberg, Peter Kabos, Austin E Gillen, et al.
Transplantation Direct|February 25, 2025
Feasibility and Optimization of Donation Advisor: a Decision Support Tool for Deceased Organ Donation and TransplantationSonny Dhanani, Rashi Ramchandani, Jill Allan, et al.
Clinical Breast Cancer|October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerNeil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2025
A Co-Clinical Trial of Exercise Therapy in Breast Cancer PreventionLee W Jones, Jessica A Lavery, Brandon L Tsai, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial LocalizationNir Ben-Chetrit, Xiang Niu, Jesus Sotelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Pageof 26